Malaria vaccine trial shows lower efficacy in younger than in older infantsBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e7665 (Published 13 November 2012) Cite this as: BMJ 2012;345:e7665
- Anne Gulland
A candidate malaria vaccine has produced disappointing results, showing lower efficacy in young babies than it does in older infants, the latest trial data show.
The efficacy of the vaccine RTS,S/AS01 in infants aged 6-12 weeks against clinical and severe malaria was 31% and 37%, respectively, found the study, published in the New England Journal of Medicine.1 Last year phase 1 clinical trials of the same vaccine in infants aged 5-17 months showed an efficacy rate of 56% for clinical malaria and 47% for severe malaria.2
Salim Abdulla, principal investigator in the trial, which is being conducted by a partnership between the drug firm GlaxoSmithKline, the Malaria Vaccine Initiative, and 11 African research centres, said that the study showed the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial